Drug Profile
ALPHA 0602
Alternative Names: Alpha 602; ALPHA-0602; ND-602; Progranulin gene therapy - Alpha cognitionLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Neurodyn
- Developer AlphaCognition
- Class Antidementias; Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference; Progranulin protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Spinal muscular atrophy
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 15 Feb 2024 ALPHA 0602 is available for licensing as of 12 Feb 2024. https://www.alphacognition.com/contact/
- 27 Sep 2023 Preclinical trials in Spinal muscular atrophy in Canada (Parenteral) (Alpha Cognition pipeline, September 2023)
- 15 Jun 2022 The European Patent Office confirms the patentability of EP3 009 143 for motor neuron disease